191 related articles for article (PubMed ID: 37841238)
1. Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review.
Fang W; Gao Y; Shi X; Zhang X; Zhou S; Zhu H; Yan W; Wang H
Front Immunol; 2023; 14():1243773. PubMed ID: 37841238
[TBL] [Abstract][Full Text] [Related]
2. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
3. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
4. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.
Marchand L; Disse E; Dalle S; Reffet S; Vouillarmet J; Fabien N; Thivolet C; Cugnet-Anceau C
Acta Diabetol; 2019 Dec; 56(12):1239-1245. PubMed ID: 31423559
[TBL] [Abstract][Full Text] [Related]
5. Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis).
Sayed Ahmed A; Abreo M; Thomas A; Chari ST
Curr Opin Gastroenterol; 2022 Sep; 38(5):516-520. PubMed ID: 35881977
[TBL] [Abstract][Full Text] [Related]
6. [Immune Checkpoint Inhibitors Related Diabetes Mellitus:
A Report of 2 Cases and Literature Review].
Ren Y; Zhang L; Wang Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):61-65. PubMed ID: 35078286
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors.
Hori Y; Naitoh I; Naiki-Ito A; Kawai T; Yoshida M; Kato A; Kachi K; Sahashi H; Adachi A; Toyohara T; Kito Y; Yamamoto T; Takahashi S; Kataoka H
Clin Transl Gastroenterol; 2024 Apr; 15(4):e00667. PubMed ID: 38088372
[TBL] [Abstract][Full Text] [Related]
8. Type 1 diabetes related to immune checkpoint inhibitors.
Tachibana M; Imagawa A
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101657. PubMed ID: 35450793
[TBL] [Abstract][Full Text] [Related]
9. Two different immune related adverse events occured at pancreas after nivolumab in an advanced RCC patient.
Yilmaz M; Baran A
J Oncol Pharm Pract; 2022 Jan; 28(1):255-258. PubMed ID: 34250849
[TBL] [Abstract][Full Text] [Related]
10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
11. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
[TBL] [Abstract][Full Text] [Related]
13. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis.
Shirwaikar Thomas A; Chari ST
Curr Gastroenterol Rep; 2023 Oct; 25(10):255-259. PubMed ID: 37845557
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management.
Liu Y; Zhang H; Zhou L; Li W; Yang L; Li W; Li K; Liu X
Front Oncol; 2021; 11():627612. PubMed ID: 33732647
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
Kramer S; van Hee K; Blokzijl H; van der Heide F; Visschedijk MC
J Immunother; 2023 Sep; 46(7):271-275. PubMed ID: 37216403
[TBL] [Abstract][Full Text] [Related]
17. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
Fischer M; Amos S; Levy L; Pollack R
Harefuah; 2021 Oct; 160(10):657-662. PubMed ID: 34689435
[TBL] [Abstract][Full Text] [Related]
18. Endocrine toxicities of immune checkpoint inhibitors.
Wright JJ; Powers AC; Johnson DB
Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
[TBL] [Abstract][Full Text] [Related]
19. A rare case of fulminant type 1 diabetes mellitus accompanied by both acute pancreatitis and myocarditis - case report.
Egashira F; Kawashima M; Morikawa A; Kosuda M; Ishihara H; Watanabe K
BMC Endocr Disord; 2020 Aug; 20(1):127. PubMed ID: 32811476
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
